NanoSphere Health Sciences Inc. Logo

NanoSphere Health Sciences Inc.

NSHS.CN

(1.8)
Stock Price

0,04 CAD

-1158.13% ROA

16.19% ROE

-0.35x PER

Market Cap.

51.201,76 CAD

0% DER

0% Yield

0% NPM

NanoSphere Health Sciences Inc. Stock Analysis

NanoSphere Health Sciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

NanoSphere Health Sciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (17.27%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

The stock's low PBV ratio (-0.08x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROA

The stock's ROA (-692.79%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

NanoSphere Health Sciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

NanoSphere Health Sciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

NanoSphere Health Sciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

NanoSphere Health Sciences Inc. Revenue
Year Revenue Growth
2005 3.479
2006 9.585 63.71%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 47.937 100%
2018 37.881 -26.55%
2019 218.034 82.63%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

NanoSphere Health Sciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 432.111 100%
2012 360.315 -19.93%
2013 10.945 -3192.04%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 123.961 100%
2019 4.844 -2459.06%
2020 0 0%
2021 59.531 100%
2022 26.907 -121.25%
2023 17.144 -56.95%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

NanoSphere Health Sciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 361.107 100%
2009 154.727 -133.38%
2010 186.819 17.18%
2011 2.615.788 92.86%
2012 2.130.128 -22.8%
2013 1.023.914 -108.04%
2014 178.336 -474.15%
2015 115.951 -53.8%
2016 621.868 81.35%
2017 1.096.734 43.3%
2018 3.916.479 72%
2019 2.252.617 -73.86%
2020 551.863 -308.18%
2021 326.470 -69.04%
2022 256.969 -27.05%
2023 180.464 -42.39%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

NanoSphere Health Sciences Inc. EBITDA
Year EBITDA Growth
2005 -25.366
2006 -31.156 18.58%
2007 -1.161.742 97.32%
2008 -5.791.551 79.94%
2009 -148.346 -3804.11%
2010 -196.713 24.59%
2011 2.959.864 106.65%
2012 -1.273.370 332.44%
2013 4.329.186 129.41%
2014 -137.032 3259.25%
2015 -98.285 -39.42%
2016 -629.056 84.38%
2017 -1.144.671 45.04%
2018 -4.467.991 74.38%
2019 -3.101.678 -44.05%
2020 -526.115 -489.54%
2021 -388.089 -35.57%
2022 -286.000 -35.7%
2023 -255.468 -11.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

NanoSphere Health Sciences Inc. Gross Profit
Year Gross Profit Growth
2005 3.479
2006 9.585 63.71%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 18.423 100%
2019 218.034 91.55%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

NanoSphere Health Sciences Inc. Net Profit
Year Net Profit Growth
2005 -25.366
2006 -31.156 18.58%
2007 -965.345 96.77%
2008 -5.169.806 81.33%
2009 162.278 3285.79%
2010 -196.720 182.49%
2011 -9.052.667 97.83%
2012 -3.730.885 -142.64%
2013 -6.450.000 42.16%
2014 -219.640 -2836.64%
2015 -133.617 -64.38%
2016 -614.680 78.26%
2017 -9.909.628 93.8%
2018 -4.514.705 -119.5%
2019 -3.489.626 -29.38%
2020 -616.815 -465.75%
2021 -354.169 -74.16%
2022 -277.504 -27.63%
2023 -165.900 -67.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

NanoSphere Health Sciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 -306
2006 -375 18.67%
2007 -424 11.56%
2008 -2.207 80.79%
2009 72 3208.45%
2010 -84 184.52%
2011 -241 65.15%
2012 -79 -205.06%
2013 -87 8.14%
2014 -1 -8500%
2015 0 0%
2016 -1 0%
2017 -18 100%
2018 -1 0%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

NanoSphere Health Sciences Inc. Free Cashflow
Year Free Cashflow Growth
2005 685
2006 -29.025 102.36%
2007 -4.369.078 99.34%
2008 -703.847 -520.74%
2009 398.487 276.63%
2010 -4.739.814 108.41%
2011 -6.528.578 27.4%
2012 -3.974.544 -64.26%
2013 -1.656.728 -139.9%
2014 -378.251 -338%
2015 -53.602 -605.66%
2016 -228.717 76.56%
2017 -1.266.202 81.94%
2018 -3.541.049 64.24%
2019 -1.132.517 -212.67%
2020 -47.257 -2296.51%
2021 -64.680 26.94%
2022 -67.660 4.4%
2023 -26.788 -152.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

NanoSphere Health Sciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2005 685
2006 -29.025 102.36%
2007 -118.116 75.43%
2008 -609.511 80.62%
2009 404.826 250.56%
2010 -4.738.810 108.54%
2011 -1.648.671 -187.43%
2012 -2.230.714 26.09%
2013 -731.836 -204.81%
2014 -378.251 -93.48%
2015 -53.602 -605.66%
2016 -228.717 76.56%
2017 -1.261.117 81.86%
2018 -3.238.880 61.06%
2019 -1.079.519 -200.03%
2020 -47.257 -2184.36%
2021 -64.680 26.94%
2022 -67.660 4.4%
2023 -26.788 -152.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

NanoSphere Health Sciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2005 0
2006 0 0%
2007 4.250.962 100%
2008 94.336 -4406.19%
2009 6.338 -1388.42%
2010 1.004 -531.9%
2011 4.879.907 99.98%
2012 1.743.831 -179.84%
2013 924.892 -88.54%
2014 0 0%
2015 0 0%
2016 0 0%
2017 5.085 100%
2018 302.169 98.32%
2019 52.998 -470.15%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

NanoSphere Health Sciences Inc. Equity
Year Equity Growth
2005 313.346
2006 281.061 -11.49%
2007 6.382.716 95.6%
2008 129.543 -4827.1%
2009 489.351 73.53%
2010 4.917.631 90.05%
2011 5.856.377 16.03%
2012 6.375.694 8.15%
2013 -376.361 1794.04%
2014 -134.836 -179.13%
2015 -88.572 -52.23%
2016 787.224 111.25%
2017 3.681.016 78.61%
2018 837.878 -339.33%
2019 -919.494 191.12%
2020 -1.453.791 36.75%
2021 -1.075.478 -35.18%
2022 -1.311.875 18.02%
2023 -1.309.284 -0.2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

NanoSphere Health Sciences Inc. Assets
Year Assets Growth
2005 318.943
2006 291.867 -9.28%
2007 7.776.490 96.25%
2008 325.154 -2291.63%
2009 504.518 35.55%
2010 5.000.449 89.91%
2011 6.131.043 18.44%
2012 6.879.552 10.88%
2013 95.882 -7075.09%
2014 95.390 -0.52%
2015 181.582 47.47%
2016 1.023.702 82.26%
2017 3.848.416 73.4%
2018 1.319.250 -191.71%
2019 333.722 -295.31%
2020 55.189 -504.69%
2021 132.514 58.35%
2022 60.049 -120.68%
2023 19.021 -215.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

NanoSphere Health Sciences Inc. Liabilities
Year Liabilities Growth
2005 5.597
2006 10.806 48.21%
2007 1.393.774 99.22%
2008 195.611 -612.52%
2009 15.168 -1189.71%
2010 82.818 81.69%
2011 274.666 69.85%
2012 503.858 45.49%
2013 472.243 -6.69%
2014 230.226 -105.12%
2015 270.154 14.78%
2016 236.478 -14.24%
2017 167.400 -41.26%
2018 481.372 65.22%
2019 1.253.216 61.59%
2020 1.508.980 16.95%
2021 1.207.992 -24.92%
2022 1.371.924 11.95%
2023 1.328.305 -3.28%

NanoSphere Health Sciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.02
Price to Earning Ratio
-0.35x
Price To Sales Ratio
0x
POCF Ratio
-2.75
PFCF Ratio
-1.83
Price to Book Ratio
-0.06
EV to Sales
0
EV Over EBITDA
-0.13
EV to Operating CashFlow
-1.42
EV to FreeCashFlow
-1.42
Earnings Yield
-2.87
FreeCashFlow Yield
-0.55
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.25
Graham NetNet
-0.13

Income Statement Metrics

Net Income per Share
-0.02
Income Quality
0.1
ROE
0.16
Return On Assets
-11.58
Return On Capital Employed
0.21
Net Income per EBT
0.83
EBT Per Ebit
0.85
Ebit per Revenue
0
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.2
Return on Tangible Assets
-11.58
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,13
Tangible Book Value per Share
-0.13
Shareholders Equity per Share
-0.13
Interest Debt per Share
-0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.04
Current Ratio
0.01
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

NanoSphere Health Sciences Inc. Dividends
Year Dividends Growth

NanoSphere Health Sciences Inc. Profile

About NanoSphere Health Sciences Inc.

NanoSphere Health Sciences Inc., a nano-biotechnology company, focuses on providing biologically active compounds in the United States and Canada. It offers NanoSphere Deliver System, a platform using nanotechnology in the bio delivery of supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

CEO
Mr. Michael Alexander Iverson
Employee
0
Address
1090 West Georgia Street
Vancouver, V6E 3V7

NanoSphere Health Sciences Inc. Executives & BODs

NanoSphere Health Sciences Inc. Executives & BODs
# Name Age
1 Mr. Michael Alexander Iverson
Chairman of the Board & Interim Chief Financial Officer
70
2 Dr. Richard Clark Kaufman B.S., M.S., Ph.D.
Co-Founder & Director
70
3 Mr. Toby Lim
Corporate Secretary & Independent Director
70
4 Dr. Terry Grossman M.D.
Co-Founder & Chief Medical Director
70
5 Ms. Kate Wells
Chief Marketing Officer of NanoSphere Health Sciences, LLC
70

NanoSphere Health Sciences Inc. Competitors